Diabetes, physical activity participation and exercise capacity in patients with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 67, Issue 6, 2013, Pages 451-456

  Vancampfort, Davy ^a,b   De Hert, Marc ^a   Sweers, Kim ^a   De Herdt, Amber ^a,b   Detraux, Johan ^a   Probst, Michel ^a,b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

diabetes; exercise; physical activity; physical fitness; schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; GLUCOSE; MOOD STABILIZER; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DIABETIC PATIENT; DIET RESTRICTION; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NEGATIVE SYNDROME; PATIENT PARTICIPATION; PHYSICAL ACTIVITY; QUESTIONNAIRE; SCHIZOPHRENIA; SMOKING;

DIABETES; EXERCISE; PHYSICAL ACTIVITY; PHYSICAL FITNESS; SCHIZOPHRENIA;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; DIABETES COMPLICATIONS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EXERCISE TOLERANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR ACTIVITY; PSYCHIATRIC STATUS RATING SCALES; QUESTIONNAIRES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; WALKING; YOUNG ADULT;

EID: 84883445687     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/pcn.12077     Document Type: Article

References (40)

1. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52-77.
2. De Hert M, Detraux J, Vancampfort D, et al. Severe mental illness and diabetes type 2. Psychiatrie Grundl. Perspekt. 2012; 3: 159-164.
3. Hansen T, Ingason A, Djurovic S, et al. At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol. Psychiatry 2011; 70: 59-63.
4. Lin PI, Shuldiner AR,. Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes. Schizophr. Res. 2010; 123: 234-243.
5. Argo T, Carahan R, Barnett M, Holman TL, Perry PJ,. Diabetes prevalence estimates in schizophrenia and risk factor assessment. Ann. Clin. Psychiatry 2011; 23: 117-124.
6. Saddichha S, Manjunatha N, Ameen S, Akhtar S,. Diabetes and schizophrenia: Effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr. Scand. 2008; 117: 342-347.
7. Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K,. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis. Br. J. Psychiatry 2008; 192: 406-411.
8. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU,. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat. Rev. Endocrinol. 2012; 8: 114-126.
9. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU,. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone, and paliperidone in the treatment of schizophrenia and bipolar disorder: A systematic review and exploratory meta-analysis. CNS Drugs 2012; 26: 733-759.
10. Correll CU,. From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry 2010; 25: 12-21.
11. De Hert M, Vancampfort D, Correll CU, et al. Guidelines for screening and monitoring of cardiometabolic risk in schizophrenia: Systematic evaluation. Br. J. Psychiatry 2011; 199: 99-105.
12. Cimo A, Stergiopoulos E, Cheng C, Bonato S, Dewa CS,. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: A systematic review. BMC Psychiatry 2012; 12: 24.
13. Mitchell AJ, Delaffon V, Vancampfort D, Correll CU, De Hert M,. Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: Systematic review and meta-analysis of screening practices. Psychol. Med. 2012; 42: 125-147.
14. Vancampfort D, Probst M, Skjaerven LH, et al. A systematic review of the benefits of physical therapy within a multidisciplinary care approach of patients with schizophrenia. Phys. Ther. 2012; 92: 11-23.
15. Vancampfort D, De Hert M, Skjaerven LH, et al. International Organization of Physical Therapy in Mental Health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia. Disabil. Rehabil. 2012; 34: 1-12.
16. Manu P, Correll CU, van Winkel R, Wampers M, De Hert M,. Prediabetes in patients treated with antipsychotic drugs. J. Clin. Psychiatry 2012; 73: 460-466.
17. Vancampfort D, Knapen J, Probst M, Scheewe T, Remans S, De Hert M,. A systematic review of correlates of physical activity in patients with schizophrenia. Acta Psychiatr. Scand. 2012; 125: 352-362.
18. Vancampfort D, Sweers K, Probst M, et al. The association of metabolic syndrome with physical activity performance in patients with schizophrenia. Diabetes Metab. 2011; 37: 318-323.
19. Larose J, Sigal RJ, Khandwala F, et al. Associations between physical fitness and HbA1c in type 2 diabetes mellitus. Diabetologia 2011; 54: 93-102.
20. Grundy SM, Barlow CE, Farrell SW, Vega GL, Haskell WL,. Cardiorespiratory fitness and metabolic risk. Am. J. Cardiol. 2012; 109: 988-993.
21. Gregg EW, Sorlie P, Paulose-Ram R, et al. Prevalence of lower-extremity disease in the US adult population ≥40 years of age with and without diabetes: 1999-2000 national health and nutrition examination survey. Diabetes Care 2004; 27: 1591-1597.
22. Chen SY, Wu YT, Wang SS,. The relationship between exercise performance and peripheral circulation in patients with peripheral arterial occlusive disease. Angiology 2001; 52: 253-258.
23. Dolan NC, Liu K, Criqui MH, et al. Peripheral artery disease, diabetes, and reduced lower extremity functioning. Diabetes Care 2002; 25: 113-120.
24. De Hert M, Van Eyck D, Hanssens L, et al. Oral glucose tolerance tests in treated patients with schizophrenia. Data to support an adaptation of the proposed guidelines for monitoring of patients on second generation antipsychotics? Eur. Psychiatry 2006; 21: 224-226.
25. van Winkel R, De Hert M, Van Eyck D, et al. Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: Evaluation of incidence and screening methods. J. Clin. Psychiatry 2006; 67: 1493-1500.
26. World Health Organization. Definition and Diagnosis of Diabetes Mellitus and Intermediate Hyperglycemia. Report of A WHO Consultation. WHO, Geneva, 2006.
27. American Thoracic Society. ATS statement: Guidelines for the six-minute walk test. Am. J. Respir. Crit. Care Med. 2002; 166: 111-117.
28. Baecke J, Burema J, Frijters J,. A short questionnaire for the measurement of habitual physical activity in epidemiological studies. Am. J. Clin. Nutr. 1982; 36: 936-942.
29. Vancampfort D, Probst M, Sweers K, Maurissen K, Knapen J, De Hert M,. Relationships between obesity, functional exercise capacity, physical activity participation and physical self perception in people with schizophrenia. Acta Psychiatr. Scand. 2011; 123: 423-430.
30. Vancampfort D, Probst M, Maurissen K, et al. Reliability, minimal detectable changes, practice effects and correlates of the 6-min walk test in patients with schizophrenia. Psychiatry Res. 2011; 187: 62-67.
31. De Hert M, Bussel J, Lindström E, Abrahams F, Franens C, Peuskens J,. PECC, Psychosis Evaluation Tool for Common Use by Caregivers. EPO, Antwerpen, 1998.
32. De Hert M, Wampers M, Thys E, Wieselgen I, Lindström E, Peuskens J,. Validation study of PECC (Psychosis Evaluation tool for Common use by Caregivers): Interscale validity and inter-rater reliability. Int. J. Psychiatr. Clin. Pract. 2002; 6: 135-140.
33. Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ,. International consensus study of antipsychotic dosing. Am. J. Psychiatry 2010; 167: 686-693.
34. Ingle L, Reddy P, Clark AL, Cleland JGF,. Diabetes lowers six-minute walk test performance in heart failure. J. Am. Coll. Cardiol. 2006; 47: 1909-1910.
35. van Sloten TT, Savelberg HH, Duimel-Peeters IG, et al. Peripheral neuropathy, decreased muscle strength and obesity are strongly associated with walking in persons with type 2 diabetes without manifest mobility limitations. Diabetes Res. 2011; 91: 32-39.
36. Vanhees L, Lefevre J, Philippaerts R, et al. How to assess physical activity? How to assess physical fitness? Eur. J. Cardiovasc. Prev. Rehabil. 2005; 12: 102-114.
37. Peet M,. Diet, diabetes and schizophrenia: Review and hypothesis. Br. J. Psychiatry 2004; 47: 102-105.
38. De Hert M, Cohen D, Bobes J, et al. Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, and recommendations at the system and individual levels. World Psychiatry 2011; 10: 138-151.
39. Colberg SR, Sigal RJ, Fernhall B, et al. Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: Joint position statement. Diabetes Care 2010; 33: e147-e167.
40. American Diabetes Association. Standards of medical care in diabetes-2011. Diabetes Care 2011; 34: 11-61.